Last reviewed · How we verify

Tretinoin gel

Bausch Health Americas, Inc. · FDA-approved active Small molecule

Tretinoin is a vitamin A derivative that binds to retinoic acid receptors in the nucleus, promoting cell differentiation and reducing sebum production and comedone formation.

Tretinoin is a vitamin A derivative that binds to retinoic acid receptors in the nucleus, promoting cell differentiation and reducing sebum production and comedone formation. Used for Acne vulgaris, Photoaging and fine wrinkles, Acute promyelocytic leukemia (systemic formulation).

At a glance

Generic nameTretinoin gel
Also known asRetin-A Micro Pump, Retin-A MICRO Gel, Retin-A Micro Gel 0.1% Pump, Retin-A Micro Gel 0.04% Pump
SponsorBausch Health Americas, Inc.
Drug classRetinoid
TargetRetinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Tretinoin acts as a ligand for nuclear retinoic acid receptors (RAR and RXR), which regulate gene transcription involved in cell proliferation and differentiation. In acne, it normalizes follicular epithelial cell turnover, reduces sebaceous gland activity, and decreases comedone formation. It also has anti-inflammatory properties and promotes collagen remodeling, making it effective for both acne and photoaging.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: